Innate Pharma (NASDAQ:IPHA – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research report issued to clients and investors on Wednesday, Benzinga reports. They presently have a $11.50 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 345.74% from the stock’s previous close.
Separately, Citigroup decreased their target price on shares of Innate Pharma from $12.00 to $8.00 in a research note on Monday, September 18th.
Innate Pharma Trading Up 13.7 %
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in Innate Pharma by 27.4% in the 1st quarter. BlackRock Inc. now owns 504,408 shares of the company’s stock worth $1,695,000 after buying an additional 108,335 shares during the period. Jane Street Group LLC raised its holdings in Innate Pharma by 156.3% in the 1st quarter. Jane Street Group LLC now owns 37,736 shares of the company’s stock worth $127,000 after purchasing an additional 23,012 shares in the last quarter. Balyasny Asset Management LLC purchased a new stake in shares of Innate Pharma in the 3rd quarter worth about $32,000. Millennium Management LLC lifted its position in shares of Innate Pharma by 389.8% in the 4th quarter. Millennium Management LLC now owns 71,684 shares of the company’s stock worth $267,000 after purchasing an additional 57,050 shares during the period. Finally, Optiver Holding B.V. boosted its stake in shares of Innate Pharma by 112.3% during the 1st quarter. Optiver Holding B.V. now owns 224,097 shares of the company’s stock valued at $636,000 after purchasing an additional 118,563 shares in the last quarter. Hedge funds and other institutional investors own 0.29% of the company’s stock.
Innate Pharma Company Profile
Innate Pharma SA, a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), an Anti-C5aR Antibody; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager.
- Five stocks we like better than Innate Pharma
- How to Invest in Casino Stocks
- 3 intriguing late-week earnings plays for short-term traders
- The Most Important Warren Buffett Stock for Investors: His Own
- Datadog is about to hit 52-week highs, and there’s more to come
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Left for dead, Tower Semiconductor is a phoenix rising
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.